Evidence map›Paper›PMID 31927599›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2020

Deletion of FHL2 in fibroblasts attenuates fibroblasts activation and kidney fibrosis via restraining TGF-β1-induced Wnt/β-catenin signaling.

Ying Duan, Yumei Qiu, Xiaowen Huang, Chunsun Dai, Junwei Yang, Weichun He

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. The roles of FHL2 in cancer.Clinical and experimental medicine · 2023
    Review
  10. Article
  11. Genes · 2022
    Article
  12. Article
  13. Stiffness is associated with hepatic stellate cell heterogeneity during liver fibrosis.American journal of physiology. Gastrointestinal and liver physiology · 2022
    Article
  14. Article
  15. MRTF: Basic Biology and Role in Kidney Disease.International journal of molecular sciences · 2021
    Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ying DuanCenter for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210003, Jiangsu, China.
Yumei QiuCenter for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210003, Jiangsu, China.
Xiaowen HuangCenter for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210003, Jiangsu, China.
Chunsun DaiCenter for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210003, Jiangsu, China.
Junwei YangCenter for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210003, Jiangsu, China.
Weichun HeCenter for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210003, Jiangsu, China. heweichun@njmu.edu.cn.ORCID 0000-0001-5685-7802
Second Affiliated Hospital of Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Four-and-a-half LIM domains protein 2 (FHL2) has been proposed involving in β-catenin activity. We previously reported that FHL2 mediates TGF-β1-induced tubular epithelial-to-mesenchymal transition through activating Wnt/β-catenin signaling. However, the potential role and mechanism for FHL2 in TGF-β1-induced fibroblast activation and kidney fibrosis remains unknown. Here, we initially observed higher levels of FHL2 expression in fibrotic kidneys from both patients and mice, especially in α-smooth muscle actin (α-SMA)-positive cells in the interstitium. In cultured interstitial fibroblasts, FHL2 expression was induced by TGF-β1. Knockdown of FHL2 remarkably suppressed TGF-β1-induced α-SMA, type I collagen, and fibronectin expression, while overexpression of FHL2 was sufficient to activate fibroblasts. In mice, fibroblast-specific deletion of FHL2 diminished renal induction of α-SMA, type I collagen, and fibronectin and interstitial extracellular matrix deposition at 2 weeks after ureteral obstruction. We next investigated Wnt/β-catenin activity and found that β-catenin was activated in most FHL2-positive cells in renal interstitium from mice with obstructive nephropathy. In vitro, TGF-β1 induced a physical interaction between FHL2 and β-catenin, especially in the nucleus. Downregulation of FHL2 inhibited TGF-β1-induced active β-catenin upregulation, β-catenin nuclear translocation, and β-catenin-mediated transcription, whereas overexpression of FHL2 was able to activate Wnt/β-catenin signaling. FHL2 overexpression-induced β-catenin-mediated gene transcription could be hindered by ICG-001, but FHL2 overexpression-induced upregulation of active β-catenin could not be. Collectively, this study reveals that the signal regulatory effect of FHL2 on β-catenin plays an important role in TGF-β1-induced fibroblast activation and kidney fibrosis.

Indexed as

Transforming Growth Factor beta1Wnt Signaling PathwayAnimalsFibroblastsFibrosisHumansKidneyKidney DiseasesLIM-Homeodomain ProteinsMaleMice, Inbred C57BLMice, TransgenicMuscle ProteinsRatsTranscription FactorsFHL2 protein, humanFhl2 protein, mouseLIM-Homeodomain ProteinsMuscle ProteinsTranscription FactorsTransforming Growth Factor beta1FHL2FibroblastKidney fibrosisTGF-β1β-Catenin

Identifiers

PMID31927599
OpenAlexW3000030544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.